Neurosciences
Neurovascular Diseases
Joan Montaner Villalonga
Researchers
José Alvarez Sabin, María Pilar Delgado Martínez, Israel Fernandez Cadenas, Maria Mar Hernandez Guillamon, Carlos Molina Cateriano, Marc Ribó Jacobi, David Rodríguez Luna, Anna Rosell Novel, Xavier Salas Puig, Estevo Santamarina Pérez
Researchers in training
Alejandro Bustamante Rangel, Caty Carrera Vasconez, Sofia Fernandez De Re Alda, Marina Gabriel Salazar, Victor Llombart Sebastià, Feifei Ma , Cristina Merino Zamorano, Alba Simats Oriol, Andrea Vilar Bergua
Nursing, technical and administrative staff
Cristina Boada Llamas, Sandra Boned Riera, Carole Conforti , Natalia Corbeto Lopez, Teresa Garcia Berrocoso, Dolors Giralt Casellas, Gloria Monts. González Cuevas, Jesus Maria Juega Mariño, Gonzalo Pablo Mazuela Aguila, Alex Montañola Pujol, Estefania Montiel , Anna Morancho Retana, Mª Angeles Muchada López, Cristina Nafría Perez, Elena Ostos Roldan, Gonzalo Pablo Mazuela Aguila, Jorge Pagola Pérez Blanca, Anna Penalba Morenilla, Manuel Quintana Luque, Yolanda Riba Llena, Silvia Ruiz Álvarez, Mireia Sanchis Marin, Estela Sanjuan Menendez, Ángela Vega Salvatierra
SUMMARY
Our group has identified several blood biomarkers that were shown to be predictive of different stroke subtypes.Together with seven other centres in Catalonia, our group carried out the StrokeChip study, which included more than 1,300 patients with suspected stroke, to look for biomarkers for stroke diagnosis.
In 2014 and thanks to a project funded by the Ministerio de Economía y Competitividad we started a second phase: Point of care device for stroke diagnosis by plasmatic biomarkers, 2-Stroke-Chip.
By means of brain proteomics we have identified potential simvastatin targets in acute phase of stroke in a rat embolic model.
In 2014 we started the project “Genetic Architecture of Human Brain Ischemia” funded by the National Institutes of Health (NIH).
PUBLICATIONS
- Delgado P, Riba-Llena I, Tovar JL, Jarca CI, Mundet X, López-Rueda A, Orfila F, Llussà J, Manresa JM, Alvarez-Sabín J, Nafría C, Fernández JL, Maisterra O, Montaner J; ISSYS Investigators*.
Prevalence and associated factors of silent brain infarcts in a Mediterranean cohort of hypertensives.
Hypertension. 2014 Sep;64(3):658-63.
I.F.: 7.632 - Duello KM, Nagel JP, Blackshear JL, Freeman WD, Montaner J, Garcia-Berrocoso T.
B-type natriuretic peptides and mortality after stroke: a systematic review and meta-analysis.
Neurology. 2014 Jul 15;83(3):292-3.
I.F.: 8.303 - Greenberg SM, Al-Shahi Salman R, Biessels GJ, van Buchem M, Cordonnier C, Lee JM, Montaner J, Schneider JA, Smith EE, Vernooij M, Werring DJ.
Outcome markers for clinical trials in cerebral amyloid angiopathy.
Lancet Neurol. 2014 Apr;13(4):419-28.
I.F.: 23.917 - Llombart V, Dominguez C, Bustamante A, Rodriguez-Sureda V, Martín-Gallán P, Vilches A, García-Berrocoso T, Penalba A, Hernández-Guillamon M, Rubiera M, Ribó M, Eschenfelder C, Giralt D, Molina CA, Alvarez-Sabín J, Rosell A, Montaner J.
Fluorescent molecular peroxidation products: a prognostic biomarker of early neurologic deterioration after thrombolysis.
Stroke. 2014 Feb;45(2):432-7. - Greenberg SM, Al-Shahi Salman R, Biessels GJ, van Buchem M, Cordonnier C, Lee JM, Montaner J, Schneider JA, Smith EE, Vernooij M, Werring DJ.
Developing biomarkers for cerebral amyloid angiopathy trials: do potential disease phenotypes hold promise? – Authors’ reply.
Lancet Neurol. 2014 Jun;13(6):540
I.F: 23.917
MAIN RESEARCH PROJECTS
View- European Project EUROHYP-1, WP9 Biomarkers (CP-IP 278709-2, FP7-HEALTH-2011-two-stage).
European multicentre, randomised, phase III clinical trial of hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke
Investigador principal
257.396 euros
Unión Europea -7º PM
2013-2016 - RO-1 (NIH2013) Genetic Architecture of Human Brain Ischemia
National Institutes of Health (NIH)
investigador principal
60.000 $ (año)
01/04/2014- 31/03/2019 - RD12/0014/0005 Red Invictus
investigador principal
Instituto de Salud Carlos III
2013-2016 - “Biomarcadores en el ictus: Optimizando las fases del proceso de traslación,desde el descubrimiento a su uso rutinario.”
Investigador principal
Instituto de Salud Carlos III
395.670 euros
2012-2015 - PROTEA: Influence of protease before, during and after stroke
Investigador principal
Ministerio de Ciencia e Innovación.
150.000 euros
2011-2014
PATENTS
- BIOMARKERS FOR THE PROGNOSIS OF ISCHEMIC STROKE
Teresa Garcia-Berrocoso and Joan Montaner
EP 12382411.2 - USE OF CCL23 AS BRAIN DAMAGE MARKER
WO2013104720 A3
PCT/EP2013/050411 - METHOD FOR DETERMINING FUNCTIONAL PATHOLOGY OF A
THROMBUS
U.S. Patent Application Number of 61/929,752 - METHODS FOR DETERMINING THE PROPENSITY OF A PATIENT FOR HEMORRHAGIC
TRANSFORMATION AFTER STROKE
Mar Hernández-Guillamon, Anna Rosell, Cristina Merino, Joan Montaner
EP13382546.3